Literature DB >> 30652608

Treatment Options in Oncology.

Cédric M Panje1, Markus Glatzer1, Charlotta Sirén1, Ludwig Plasswilm1, Paul M Putora1.   

Abstract

Multiple treatment strategies exist for many oncologic problems. In this review, we provide a summary of various reasons for the existence of multiple treatment options in oncology, including factors that concern the treating physician (eg, treatment preferences), environmental factors (eg, financial, regulatory, and scientific aspects), and individual patient-specific factors (eg, medical condition, preferences). We demonstrate the vital role of available treatment options and their origins for clinical decision making and patient communication. These aspects are particularly helpful in the process of shared decision making, which is increasingly favored in situations where there are multiple medically reasonable options.

Entities:  

Mesh:

Year:  2018        PMID: 30652608     DOI: 10.1200/CCI.18.00017

Source DB:  PubMed          Journal:  JCO Clin Cancer Inform        ISSN: 2473-4276


  8 in total

1.  Variations in Radioiodine Therapy in Europe: Decision-Making after Total Thyroidectomy.

Authors:  Flavio Forrer; Galina Farina Fischer; Ole Maas; Luca Giovanella; Martha Hoffmann; Ioannis Iakovou; Markus Luster; Jasna Mihailovic; Petra Petranovic Ovčariček; Alexis Vrachimis; Slimane Zerdoud; Paul Martin Putora
Journal:  Oncology       Date:  2021-11-17       Impact factor: 2.935

2.  Adverse events reporting in stage III NSCLC trials investigating surgery and radiotherapy.

Authors:  Thomas Iseli; Thierry Berghmans; Markus Glatzer; Achim Rittmeyer; Gilbert Massard; Valérie Durieux; Thomas Buchsbaum; Paul Martin Putora
Journal:  ERJ Open Res       Date:  2020-09-14

Review 3.  Targeting cancer via ribosome biogenesis: the cachexia perspective.

Authors:  Vandré Casagrande Figueiredo; John J McCarthy
Journal:  Cell Mol Life Sci       Date:  2021-07-01       Impact factor: 9.261

4.  Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.

Authors:  Werner Scheithauer; Paul Martin Putora; Birgit Grünberger; Wolfgang Eisterer; Ewald Wöll; Gerald Prager; Renate Schaberl-Moser; Richard Greil; Markus Glatzer
Journal:  Therap Adv Gastroenterol       Date:  2019-09-23       Impact factor: 4.409

5.  Radiotherapy for pelvic nodal recurrences after radical prostatectomy: patient selection in clinical practice.

Authors:  Cedric Panje; Thomas Zilli; Alan Dal Pra; Winfried Arnold; Kathrin Brouwer; Helena I Garcia Schüler; Silvia Gomez; Fernanda Herrera; Kaouthar Khanfir; Alexandros Papachristofilou; Gianfranco Pesce; Christiane Reuter; Hansjörg Vees; Daniel Zwahlen; Paul Martin Putora
Journal:  Radiat Oncol       Date:  2019-10-16       Impact factor: 3.481

6.  Stage III N2 non-small cell lung cancer treatment: decision-making among surgeons and radiation oncologists.

Authors:  Markus Glatzer; Pawel Leskow; Francesca Caparrotti; Olgun Elicin; Markus Furrer; Franco Gambazzi; André Dutly; Hans Gelpke; Matthias Guckenberger; Jürg Heuberger; Rolf Inderbitzi; Stefano Cafarotti; Wolfram Karenovics; Peter Kestenholz; Gregor Jan Kocher; Peter Kraxner; Thorsten Krueger; Francesco Martucci; Christoph Oehler; Mahmut Ozsahin; Alexandros Papachristofilou; Dirk Wagnetz; Kathrin Zaugg; Daniel Zwahlen; Isabelle Opitz; Paul Martin Putora
Journal:  Transl Lung Cancer Res       Date:  2021-04

7.  Progesterone, cervical cerclage or cervical pessary to prevent preterm birth: a decision-making analysis of international guidelines.

Authors:  Katharina Putora; René Hornung; Janis Kinkel; Tina Fischer; Paul Martin Putora
Journal:  BMC Pregnancy Childbirth       Date:  2022-04-23       Impact factor: 3.105

8.  International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?

Authors:  Paul Martin Putora; Pawel Leskow; Fiona McDonald; Tim Batchelor; Matthiew Evison
Journal:  ERJ Open Res       Date:  2020-02-17
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.